Dr. John Cush RheumNow
1 year 6 months ago
2024 In Memorium
Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of… https://t.co/c8xvPyXbft https://t.co/TEQihNmZnr
Dr. John Cush RheumNow
1 year 7 months ago
🚨 RheumNow Live 2025: Redefining Rheumatology 🚨
Join top experts & innovators shaping the future of rheumatology care! 💡 Cutting-edge research, interactive sessions, expert insights, & exclusive access await.
Be part of the change. Register now! 👉 https://t.co/AQbd7NC2wz… https://t.co/AcmKxGBLvb https://t.co/QlZoAhm8h8
Dr. John Cush RheumNow
1 year 7 months ago
Among SLE pts, males have a higher risk of infection compared to females. Males have a (6X) higher prevalence of pneumonia and women have more urinary tract infections. Retrospective study of 119 SLE pts (107 females, 12 males) https://t.co/M12G7hT340 https://t.co/SG7eSGzpXh
The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations. These recommendations pertain to adults 40 years or older with no known diagnosis of osteoporosis or history of fragility fracture.
Dr. John Cush RheumNow
1 year 7 months ago
QD Clinic - CREST or More?
Is this CREST or Diffuse PSS?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/eA1GijHiYu https://t.co/3EmN9WAyIR
Dr. John Cush RheumNow
1 year 7 months ago
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/WwvAhPuoGV https://t.co/M0yECxsvcr
Dr. John Cush RheumNow
1 year 7 months ago
Eltrombopag, a Potential New Treatment for ITP
A pilot trial has shown a thrombopoietin receptor agonist, eltrombopag (Promacta), to be effective in connective tissue disease-related (CTD), refractory immune thrombocytopenia (ITP).
https://t.co/hYSAEKOjq5 https://t.co/QzBNA3SWVo
Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).
Dr. John Cush RheumNow
1 year 7 months ago
Pan American Health Org announces that in 2024 saw largest dengue epidemic in the Americas, >12.6 million cases reported (3x record in 2023); 21,000 severe w/ 7,700 deaths; 90% from Argentina, Brazil, Colombia, Mexico. Most USA cases (FL, HI, TX, AZ, CA) seen in travelers… https://t.co/nhuJIP9Y8v https://t.co/QLju8uRKZ8
Dr. John Cush RheumNow
1 year 7 months ago
Alive in 2025 (1.10.2025)
Dr. Jack Cush brings in the new year with a review of the latest from RheumNow.
https://t.co/Cw94fF5nFi https://t.co/6c3Gl6GOCY
Dr. John Cush RheumNow
1 year 7 months ago
SetPoint Medical has applied to FDA for pre-market approval of Vagal nerve neuroimmune modulation device to Rx mod-severe #RA, not responding to 2 biologics. Based on RESET-RA 242 pt, 12 wk RCT showing ACR20=35% vs 24% PBO resp. SAE only 1.7%. https://t.co/d8RfXBFUSS https://t.co/Fq1qkfo1NM
Dr. John Cush RheumNow
1 year 7 months ago
Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/AuMTLo8iQO https://t.co/1icGoXKfB9
Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of millions in the future. They did the painstakingly hard work of caring for the most complex patients and did so with zeal, wonder and love for their patients. Remember them, honor them
